[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "dahhamalsoud.github.io",
    "section": "",
    "text": "This is a Quarto website.\nTo learn more about Quarto websites visit https://quarto.org/docs/websites.\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Dahham Alsoud",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "Breaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nUtility of the serum-based Endoscopic Healing Index in monitoring therapeutic response in ulcerative colitis.\nThe American Journal of Gastroenterology PMID: 37753938\nCalibration, clinical utility and specificity of clinical decision support tools in inflammatory bowel disease.\nClinical Gastroenterology and Hepatology PMID: 39461468 Analysis notebook\nReal-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nReal-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study.\nInflammatory Bowel Diseases PMID: 38215029 Analysis notebook\nBest practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.\nTherapeutic Drug Monitoring PMID: 38648666\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBeyond discrimination: a call for comprehensive assessment of clinical prediction models in inflammatory bowel disease.\nInflammatory Bowel Diseases PMID: 38460148\nUstekinumab and vedolizumab exposure is unaffected by pharmacogenetic determinants of anti-TNFs pharmacokinetics.\nInflammatory Bowel Diseases PMID: 38581670"
  },
  {
    "objectID": "publications.html#as-a-first-author",
    "href": "publications.html#as-a-first-author",
    "title": "Publications",
    "section": "",
    "text": "Breaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nUtility of the serum-based Endoscopic Healing Index in monitoring therapeutic response in ulcerative colitis.\nThe American Journal of Gastroenterology PMID: 37753938\nCalibration, clinical utility and specificity of clinical decision support tools in inflammatory bowel disease.\nClinical Gastroenterology and Hepatology PMID: 39461468 Analysis notebook\nReal-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nReal-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study.\nInflammatory Bowel Diseases PMID: 38215029 Analysis notebook\nBest practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.\nTherapeutic Drug Monitoring PMID: 38648666\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBeyond discrimination: a call for comprehensive assessment of clinical prediction models in inflammatory bowel disease.\nInflammatory Bowel Diseases PMID: 38460148\nUstekinumab and vedolizumab exposure is unaffected by pharmacogenetic determinants of anti-TNFs pharmacokinetics.\nInflammatory Bowel Diseases PMID: 38581670"
  },
  {
    "objectID": "publications.html#as-a-co-author",
    "href": "publications.html#as-a-co-author",
    "title": "Publications",
    "section": "As a co-author",
    "text": "As a co-author\n\nTailoring multi-omics to inflammatory bowel diseases: all for one and one for all.\nJournal of Crohn’s and Colitis PMID: 35150242\nLongitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.\nAlimentary Pharmacology & Therapeutics PMID: 35484689\nEvaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease.\nTherapeutic Advances in Gastroenterology PMID: 37655059\nAdalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center.\nEuropean Journal of Gastroenterology and Hepatology PMID: 36062494\nTranslating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD.\nInflammatory Bowel Diseases PMID: 34751766\nThe effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.\nBritish Journal of Clinical Pharmacology PMID: 33604964"
  },
  {
    "objectID": "publications.html#as-a-first-author-hi",
    "href": "publications.html#as-a-first-author-hi",
    "title": "Publications",
    "section": "",
    "text": "Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBreaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101"
  },
  {
    "objectID": "cv-dahhamalsoud.html",
    "href": "cv-dahhamalsoud.html",
    "title": "Curriculum Vitae",
    "section": "",
    "text": "Master of Science – Statistics and Data Science Sep 2024 – Present  Katholieke Universiteit Leuven, Leuven, Belgium\nDoctor of Philosophy – Biomedical Sciences Sep 2019 – March 2025  Katholieke Universiteit Leuven, Leuven, Belgium\n\nThesis title: Understanding Therapeutic Outcomes in Inflammatory Bowel Diseases: Insights from Clinicomics, Proteomics, and Transcriptomics.\nPomotor: Prof.Dr. Severine Vermeire ; Co-promotor: Prof.Dr. Bram Verstockt\nDefense date: March 2025\n\nMaster of Science – Health Care Management and Policy Sep 2020 – Sep 2024  Katholieke Universiteit Leuven, Leuven, Belgium\n\nMajor in “Health Care Management”\nThesis promotor: Prof.Dr. Luk Bruyneel\n\nDoctor of Medicine Sep 2008 – Nov 2015  Damascus University, Damascus, Syria"
  },
  {
    "objectID": "cv-dahhamalsoud.html#education",
    "href": "cv-dahhamalsoud.html#education",
    "title": "Curriculum Vitae",
    "section": "",
    "text": "Master of Science – Statistics and Data Science Sep 2024 – Present  Katholieke Universiteit Leuven, Leuven, Belgium\nDoctor of Philosophy – Biomedical Sciences Sep 2019 – March 2025  Katholieke Universiteit Leuven, Leuven, Belgium\n\nThesis title: Understanding Therapeutic Outcomes in Inflammatory Bowel Diseases: Insights from Clinicomics, Proteomics, and Transcriptomics.\nPomotor: Prof.Dr. Severine Vermeire ; Co-promotor: Prof.Dr. Bram Verstockt\nDefense date: March 2025\n\nMaster of Science – Health Care Management and Policy Sep 2020 – Sep 2024  Katholieke Universiteit Leuven, Leuven, Belgium\n\nMajor in “Health Care Management”\nThesis promotor: Prof.Dr. Luk Bruyneel\n\nDoctor of Medicine Sep 2008 – Nov 2015  Damascus University, Damascus, Syria"
  },
  {
    "objectID": "cv-dahhamalsoud.html#work-experiencepostgraduate-training",
    "href": "cv-dahhamalsoud.html#work-experiencepostgraduate-training",
    "title": "Curriculum Vitae",
    "section": "Work Experience/Postgraduate Training",
    "text": "Work Experience/Postgraduate Training\nPhD researcher Sep 2019 – Present\nMain objectives:\n\nEvaluate the discriminative capacity, calibration, and clinical utility of existing clinical decision support tools for predicting response to biologics in patients with inflammatory bowel disease.\n\nIdentify proteomic signatures able to predict endoscopic outcome to biologic therapy in Crohn’s disease.\n\nGain insights into the mechanisms of action of current therapies for ulcerative colitis using whole blood transcriptomics, and identify transcriptomic signatures able to predict their endoscopic outcome.\n\n\nHospitalist Physician Sep 2018 – Aug 2019  Diabetes clinic - University Hospitals Brussels, Brussels, Belgium\nResident – Clinical Pathology Sep 2017 – Aug 2018  University Hospitals Brussels, Brussels, Begium"
  },
  {
    "objectID": "cv-dahhamalsoud.html#scholarly-contributions",
    "href": "cv-dahhamalsoud.html#scholarly-contributions",
    "title": "Curriculum Vitae",
    "section": "Scholarly Contributions",
    "text": "Scholarly Contributions\n\nPublications\nPeer Review activities"
  },
  {
    "objectID": "cv-dahhamalsoud.html#software",
    "href": "cv-dahhamalsoud.html#software",
    "title": "Curriculum Vitae",
    "section": "Software",
    "text": "Software\n\nR packages: phdcocktail1852 downloads on November 09, 2024"
  },
  {
    "objectID": "cv-dahhamalsoud.html#computational-biology-skills",
    "href": "cv-dahhamalsoud.html#computational-biology-skills",
    "title": "Curriculum Vitae",
    "section": "Computational Biology Skills",
    "text": "Computational Biology Skills\n\nScripting: R, Python, and Unix for data manipulation, visualization, and predictive/bioinformatic analyses.\nBioinformatic algorithms and packages: proteomics, bulk and single-cell transcriptomics, spatial transcriptomics, metagenomics, metabolomics and multi-omics integration.\nQuarto Publishing: articles, presentations, dashboards, and websites.\nPackage Development: R, Python, and Bioconductor.\nWeb Applications Development: using Shiny, with basic knowledge of HTML, CSS, and JavaScript."
  }
]